Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis

Hemodialysis International

Volumn 17, Issue 1, 2013, Pages 67-74

  Umanath, Kausik ^a   Sika, Mohammed ^b   Niecestro, Robert ^c   Connelly, Carolyn ^c   Schulman, Gerald ^b   Koury, Mark J ^b   Lewis, Julia B ^b   Dwyer, Jamie P ^b  

^a HENRY FORD HOSPITAL   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c AKEBIA THERAPEUTICS   (United States)

Author keywords

Clinical trial; End stage renal disease (ESRD); Phosphate binder

Indexed keywords

CALCIUM; FERRIC CITRATE; IRON; PHOSPHATE BINDING AGENT; PHOSPHORUS;

ADULT; ARTICLE; BONE DISEASE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); DIALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMODIALYSIS; HUMAN; IRON BLOOD LEVEL; ISRAEL; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; TREATMENT DURATION; UNITED STATES;

ADOLESCENT; ADULT; CHELATING AGENTS; FEMALE; FERRIC COMPOUNDS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PHOSPHATES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; YOUNG ADULT;

EID: 84872673879     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2012.00711.x     Document Type: Article

References (28)

1. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl. 1999; 73:S14-S19.
2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15:2208-2218.
3. Molony DA, Murthy B. Accumulation of metals and minerals from phosphate binders. Blood Purif. 2005; 23(Suppl 1):2-11.
4. Clarkson EM, Durrant C, Phillips ME, Gower PE, Jewkes RF, de Wardener HE. The effect of a high intake of calcium and phosphate in normal subjects and patients with chronic renal failure. Clin Sci. 1970; 39:693-704.
5. Clarkson EM, Eastwood JB, Koutsaimanis KG, de Wardener HE. Net intestinal absorption of calcium in patients with chronic renal failure. Kidney Int. 1973; 3:258-263.
6. Clarkson EM, McDonald SJ, De Wardener HE. The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure. Clin Sci. 1966; 30:425-438.
7. Hsu CH. Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis. 1997; 29:641-649.
8. McDonald SJ, Clarkson EM, Dewardener HE. The effect of a large intake of calcium citrate in normal subjects and patients with chronic renal failure. Clin Sci. 1964; 26:27-39.
9. How PP, Fischer JH, Arruda JA, Lau AH. Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin. Clin J Am Soc Nephrol. 2007; 2:1235-1240.
10. Feng L, Xiao H, He X etal. Neurotoxicological consequence of long-term exposure to lanthanum. Toxicol Lett. 2006; 165:112-120.
11. Slatopolsky E, Liapis H, Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int. 2005; 68:2809-2813.
12. Sevelamer reduces the efficacy of many other drugs. Prescrire Int. 2009; 18:164-165.
13. Kays MB, Overholser BR, Mueller BA, Moe SM, Sowinski KM. Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am J Kidney Dis. 2003; 42:1253-1259.
14. Hsu CH, Patel SR, Young EW. New phosphate binding agents: Ferric compounds. J Am Soc Nephrol. 1999; 10:1274-1280.
15. Yang WC, Yang CS, Hou CC, Wu TH, Young EW, Hsu CH. An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: Ferric citrate. Nephrol Dial Transplant. 2002; 17:265-270.
16. Sika M, Koury M, Smith M, etal. Evaluation of ferric citrate as a phosphate binder in dialysis patients requiring high doses of phosphate binders. ASN Renal Week 2009. San Diego, California, 2009; TH-PO361.
17. Sika M, Sinsakul MV, Niecestro RM, Chiang S. Prolonged use of Ferric Citrate (FC) as a phosphate binder reduces IV iron use in Pts with ESRD. ASN Renal Week 2010. Denver, Colorado, 2010; SA-PO2946.
18. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42(4 Suppl 3):S1-201.
19. Collins AJ, Foley RN, Gilbertson DT, Chen SC. The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. Clin J Am Soc Nephrol. 2009; 4(Suppl 1):S5-11.
20. Chertow GM, Burke SK, Lazarus JM, etal. Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis. 1997; 29:66-71.
21. Finn WF. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: Safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol. 2006; 65:191-202.
22. Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis. 2003; 42:96-107.
23. Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int. 1999; 55:299-307.
24. Winchester JF, Rotellar C, Goggins M, Robino D, Rakowski TA, Argy WP. Calcium and phosphate balance in dialysis patients. Kidney Int Suppl. 1993; 41:S174-S178.
25. Yavuz A, Ersoy FF, Passadakis PS, etal. Phosphorus control in peritoneal dialysis patients. Kidney Int Suppl. 2008; April:S152-S158.
26. Bommer J, Locatelli F, Satayathum S, etal. Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004; 44:661-671.
27. Wu DY, Shinaberger CS, Regidor DL, McAllister CJ, Kopple JD, Kalantar-Zadeh K. Association between serum bicarbonate and death in hemodialysis patients: Is it better to be acidotic or alkalotic? Clin J Am Soc Nephrol. 2006; 1:70-78.
28. Slanina P, Frech W, Ekstrom LG, Loof L, Slorach S, Cedergren A. Dietary citric acid enhances absorption of aluminum in antacids. Clin Chem. 1986; 32:539-541.